Pharmacokinetics of netivudine, a potent anti-varicella zoster virus drug, in patients with renal impairment

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue 5, 1996, Pages 965-974

  Fillastre, J P ^a,e   Godin, M ^a   Legallicier, B ^a   Chretien, P ^b   Bidault, R ^c   Gillotin, C ^c   Wooton, R ^d   Posner, J ^d   Peck, R W ^d  

^a UNIVERSITÉ DE ROUEN   (France)

^b CEMAX Lab   (France)

^c Laboratoire Glaxo Wellcome   (France)

^d WELLCOME RESEARCH LABORATORIES   (United Kingdom)

^e Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CREATININE; DRUG METABOLITE; NETIVUDINE; NUCLEOSIDE ANALOG;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HERPES ZOSTER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; ORAL DRUG ADMINISTRATION; PLASMA CLEARANCE; TIME; URINALYSIS; VARICELLA ZOSTER VIRUS;

ADMINISTRATION, ORAL; AGED; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; BLOOD PROTEINS; CREATININE; HERPESVIRUS 3, HUMAN; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED;

EID: 0029894860     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.5.965     Document Type: Article

References (7)

1. Buick, A. R. & Sheung, C. T. (1993). Determination of 1-(β-D-arabinofuranosyl)-5-propynyluracil and a metabolite, 5 propynyl)uracil in plasma using ASTED (automated sequential trace enrichment of dialysates) combined on line with high-performance liquid chromatography. Journal of Chromatography 617, 65-70.
2. Cooper, J. D. M., Sheung, C. T. & Buick, A. R. (1994). Automated sequential trace enrichment of dialysates combined with high-performance liquid chromatography and automated heart cutting for the determination of the nucleoside 1-(Beta-D-arabinofuranosyl)-5-(1-propynyl)uracil and its metabolite 5-propyluracil in urine. Journal of Chromatography 652, 15-21.
3. Peck, R. W., Weatherley, B. C., Wootton, R., Crome, P., Holdich, T. A. & Posner, J. (1995a). Pharmacokinetics and tolerability of single oral doses of 882C87, a potent new anti-varicella-zoster virus agent, in healthy volunteers. Antimicrobial Agents and Chemotherapy 39, 20-7.
4. Peck, R. W., Wootton, R., Lee, D. R., Jackson, S. H. & Posner, J. (1995b). The bioavailability and disposition of 1-(β-D-arabinofuranosyl-5-(1-propynyl)uracil (882C87), a potent, new anti-varicella zoster virus agent. British Journal of Clinical Pharmacology 39, 143-9.
5. Purifoy, D. J., Beauchamp, L. M., De Miranda, P., Ertl, P., Lacey, S., Roberts, G. et al. (1993). Review of research leading to new anti-herpes virus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882, a specific agent for varicells zoster virus. Journal of Medical Virology, Suppl. 1, 139-45.
6. Rahim, S. G., Trivedi, V., Selway, J., Darby, G. K., Collins, P., Powell, K. L. et al. (1992). 5-Alkynyl pyrimidine nucleosides as potent selective inhibitors of varicella-zoster virus. Antiviral Chemistry and Chemotherapy 3, 293-7.
7. Wood, M. J., McKendrick, M. W., Bannister, B., Mandal, B. K., Peck, R. W. & Crooks, R. J. (1993). Preliminary pharmacokinetics and safety of 882C87 in patients with herpes zoster. Journal of Medical Virology, Suppl. 1, 154-7.